Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 16

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 16
---
 unwavering. Nonetheless, we are determined to reduce costs, especially in functional areas that don’t impact our customers. We have already taken a series of steps to materially reduce our long - term cost profile, and we have identified additional opportunities to better position the Company for profitable growth …” 2 March 17, 2025 Realignment of Leadership Structure The dedication of additional resources likely helped accelerate the Company’s resolution of its inventory challenges in China; Mr. Jiang’s continued attention to STAAR’s APAC business should, in our view, facilitate the continued recovery of that business “Wei’s knowledge of STAAR, our business, strategy, and people, combined with his 25+ year history of success in leadership roles at large multinational pharmaceutical companies in China, make him well suited for this role… Wei’s assistance in - country will accelerate the resolution of our distribution channel challenges in China and will help us to continue to successfully navigate the evolving global tariff environment.” 3 April 24, 2025 Appointment of Wei Jiang as Strategic Advisor to STAAR’s APAC Business 1. Source: STAAR Press Release, February 26, 2025. 2. Source: STAAR Press Release, March 17, 2025. 3. Source: STAAR Press Release, April 24, 2025. 1 B

Broadwood Partners, L.P. STAAR’s Recent Actions Have Strengthened the Company (Continued) 24 1. Source: STAAR Press Release, May 7, 2025. 2. Source: STAAR Press Release, May 16, 2025. 3. Source: STAAR Press Release, June 25, 2025. It is not surprising that Alcon would seek to purchase the Company before the benefits of these initiatives are fully realize d Potential Implications What STAAR Said Date Announced Milestone STAAR expects to exit fiscal 2025 having reduced its SG&A expense base by at least 11%, supporting margin expansion amid accelerating growth and expanded production “The Company is meaningfully cutting costs and is undertaking restructuring activities to reduce its SG&A run rate… The Company has identified spend reductions related to facilities, marketing, and staff that are expected to reduce the annualized SG&A run rate significantly below fiscal 2024 … The majority of the restructuring activities are focused on U.S. operations. The Company is also assessing other areas of potential savings [that] may be redeployed to fund strategic investments to drive future